7498 Results (Page 39 of 300)
Pharmaceuticals Markets Research Reports
France Castrate Resistant Prostate Cancer Therapeutics Market Analysis
France Castrate Resistant Prostate Cancer Therapeutics Market valued at $281 Mn in 2022, projected to reach $450 Mn by 2030 with a 6.10% CAGR. The key drivers of the castration-resistant prostate cancer (CRPC) therapeutics market in France include the growing prevalence of prostate cancer among an aging population, enhanced awareness, and improved screening methods, as well as the French government's increasing healthcare expenditure. The France Castrate Resistant Prostate Cancer Therapeutics Market encompasses various players across different segments, including Sanofi, Pfizer, Johnson & Johnson, Roche, Bayer, Astellas, Amgen, Ipsen, AstraZeneca, Bristol-Myers Squibb, etc, among various others.
Canada Castrate Resistant Prostate Cancer Therapeutics Market Analysis
Canada Castrate Resistant Prostate Cancer Therapeutics Market valued at $816 Mn in 2022, projected to reach $1413 Mn by 2030 with a 7.10% CAGR. The key drivers of growth include the persistent unmet medical need for a cure, which fuels extensive research and development efforts for innovative treatments, as well as the transformative impact of technological innovations such as precision medicine, and a shift towards patient-centric priorities focusing on improved quality of life and less intrusive treatment options. The Canada Castrate Resistant Prostate Cancer Therapeutics Market encompasses various players across different segments, including Pfizer, Johnson & Johnson, Bayer, Roche, Sanofi, Novartis, AstraZeneca, Apotex, Paladin Labs, Bausch etc, among various others.
Vietnam Alzheimer’s Therapeutics Market Analysis
Vietnam alzheimer’s therapeutics market valued at $24 Mn in 2022, projected to reach $49 Mn by 2030 with a 9.33% CAGR. The growing prevalence of Alzheimer's disease, which is fuelled by an aging population, is the main factor driving the market for drugs used to treat the condition. The top pharmaceutical firms in the industry currently operating in the market are Eisai, Biogen, GlaxoSmithKline, Novartis, Pfizer, Roche, Johnson & Johnson, Eli Lilly, AstraZeneca and Merck & Co.
US Alzheimer’s Therapeutics Market Analysis
US alzheimer’s therapeutics market valued at $2016 Mn in 2022, projected to reach $3490 Mn by 2030 with a 7.1% CAGR. The factors boosting the market's growth are the rising prevalence of Alzheimer's disease and the approval of therapies that can change the course of the illness. Leading pharmaceutical companies that are currently working in the market are Eisai, Biogen, Roche, Eli Lilly, Merck & Co., Genentech, AbbVie, Johnson & Johnson, Novartis and Pfizer.
UK Alzheimer’s Therapeutics Market Analysis
UK alzheimer’s therapeutics market valued at $125 Mn in 2022, projected to reach $216 Mn by 2030 with a 7.1% CAGR. One key factor propelling the market for Alzheimer's treatment medications is the rising incidence of Alzheimer's disease which is driven by an aging population. Biogen, Eisai Co, Janssen Pharmaceuticals, Novartis, Pfizer, Lundbeck, Merck & Co, AstraZeneca, Eli Lilly and Accord Healthcare are leading pharmaceutical companies currently operating in the market.
UAE Alzheimer’s Therapeutics Market Analysis
UAE alzheimer’s therapeutics market valued at $24 Mn in 2022, projected to reach $52 Mn by 2030 with a 10.1% CAGR. As the population ages, the prevalence of Alzheimer's disease rises, driving demand for Alzheimer's treatment drugs, one of the major factors driving the market's growth. Leading pharmaceutical companies that are currently working in the market are Pfizer, Eisai, Janssen, Biogen, Roche, Novartis, Lundbeck, Otsuka Pharmaceutical, Teva Pharmaceutical and Sun Pharmaceutical.
Spain Alzheimer’s Therapeutics Market Analysis
Spain alzheimer’s therapeutics market valued at $93 Mn in 2022, projected to reach $73 Mn by 2030 with a 8.1% CAGR. One key factor propelling the market for Alzheimer's treatment medications is the rising incidence of Alzheimer's disease which is driven by an aging population. Biogen, Eisai Co, Janssen Pharmaceuticals, Novartis, Pfizer, Lundbeck, Merck & Co, AstraZeneca, Eli Lilly and STA Pharmaceutical are leading pharmaceutical companies currently operating in the market.
South Africa Alzheimer’s Therapeutics Market Analysis
South Africa alzheimer’s therapeutics market valued at $31 Mn in 2022, projected to reach $69 Mn by 2030 with a 10.33% CAGR. The growing prevalence of Alzheimer's disease, which is fuelled by an aging population, is the main factor driving the market for drugs used to treat the condition. The leading pharmaceutical companies currently working in the industry are Pfizer, Eisai, Biogen, Merck & Co., Novartis, Roche, Johnson & Johnson, Eli Lilly, AstraZeneca and GlaxoSmithKline.
Singapore Alzheimer’s Therapeutics Market Analysis
Singapore alzheimer’s therapeutics market valued at $6 Mn in 2022, projected to reach $12 Mn by 2030 with a 9.7% CAGR. The market for medications used to treat Alzheimer's disease is mostly driven by the condition's increasing prevalence, which is fuelled by an aging population. The top pharmaceutical firms in the industry currently operating in the market are Eisai, Biogen, GlaxoSmithKline, Novartis, Pfizer, Roche, Johnson & Johnson, Eli Lilly, AstraZeneca and Merck & Co.
Saudi Arabia Alzheimer’s Therapeutics Market Analysis
Saudi Arabia alzheimer’s therapeutics market valued at $82 Mn in 2022, projected to reach $183 Mn by 2030 with a 10.6% CAGR. The increasing number of individuals suffering from Alzheimer's disease and the approval of therapies that can slow the disease's progression are driving the market's expansion. Leading pharmaceutical companies that are currently working in the market are Eisai, Janssen Pharmaceuticals, Biogen, Eli Lilly, Roche, Merck, Genentech, AbbVie, Novartis and Pfizer.
Philippines Alzheimer’s Therapeutics Market Analysis
Philippines alzheimer’s therapeutics market valued at $11 Mn in 2022, projected to reach $22 Mn by 2030 with a 9.6% CAGR. The market for medications used to treat Alzheimer's disease is mostly driven by the condition's increasing prevalence, which is fuelled by an aging population. The top pharmaceutical firms in the industry currently operating in the market are Pfizer, Novartis, Johnson & Johnson, Roche, Eli Lilly, Biogen, AstraZeneca, Merck & Co., AbbVie and Eisai.
Mexico Alzheimer’s Therapeutics Market Analysis
Mexico alzheimer’s therapeutics market valued at $72 Mn in 2022, projected to reach $147 Mn by 2030 with a 9.35% CAGR. One of the main factors propelling the market's growth is the rising demand for Alzheimer's treatment pharmaceuticals as a result of the increasing prevalence of Alzheimer's disease among the aging population. Top leading pharmaceutical companies presently operating in the market are Pfizer, Janssen, Eisai, Biogen, Novartis, Roche, Lundbeck, Otsuka Pharmaceutical, Teva Pharmaceutical and Sun Pharmaceutical.
Kenya Alzheimer’s Therapeutics Market Analysis
Kenya alzheimer’s therapeutics market valued at $3 Mn in 2022, projected to reach $7 Mn by 2030 with a 10.2% CAGR. The growing prevalence of Alzheimer's disease, which is fuelled by an aging population, is the main factor driving the market for drugs used to treat the condition. The leading pharmaceutical companies currently working in the industry are Eisai, Biogen, GlaxoSmithKline, Novartis, Pfizer, Roche, Johnson & Johnson, Eli Lilly, AstraZeneca and Merck & Co.
Japan Alzheimer’s Therapeutics Market Analysis
Japan alzheimer’s therapeutics market valued at $298 Mn in 2022, projected to reach $621 Mn by 2030 with a 9.6% CAGR. The growing prevalence of Alzheimer's disease, which is fuelled by an aging population, is one major factor driving the market for drugs used to treat the condition. The leading pharmaceutical companies currently operating in the market are Eisai, Otsuka Holdings Co., Astellas Pharma Inc., Mitsubishi Tanabe Pharma Corporation, Sumitomo Dainippon Pharma Co., Takeda Pharmaceutical Company, Roche Holding, Novartis, Pfizer, and Lundbec.
Indonesia Alzheimer’s Therapeutics Market Analysis
Indonesia alzheimer’s therapeutics market valued at $29 Mn in 2022, projected to reach $58 Mn by 2030 with a 9.1% CAGR. The growing prevalence of Alzheimer's disease, which is fuelled by an aging population, is one major factor driving the market for drugs used to treat the condition. The leading pharmaceutical companies currently operating in the market are Eisai Co., Otsuka Pharmaceutical Co., Janssen Pharmaceuticals, Novartis, Pfizer, Lundbeck, Merck & Co., Sanofi, PT Kalbe Farma and PT Kimia Farma.
Germany Alzheimer’s Therapeutics Market Analysis
Germany alzheimer’s therapeutics market valued at $176 Mn in 2022, projected to reach $309 Mn by 2030 with a 7.3% CAGR. One major driver of the market's expansion is the rising need for drugs used to treat Alzheimer's disease, which is mostly due to the disease's rising incidence in elderly population. Eisai, Pfizer, Janssen, Novartis, Biogen, Roche, Lundbeck, Otsuka Pharmaceutical, Teva Pharmaceutical and Sun Pharmaceutical are leading pharmaceutical companies presently operating in the market.
France Alzheimer’s Therapeutics Market Analysis
France alzheimer’s therapeutics market valued at $132 Mn in 2022, projected to reach $246 Mn by 2030 with a 8.1% CAGR. One of the key reasons driving the market's expansion for the growing demand for medicines used in Alzheimer's treatment is due to the disease's rising incidence among the elderly population. Top leading pharmaceutical companies presently operating in the market are Eisai, Pfizer, Janssen, Novartis, Biogen, Roche, Lundbeck, Otsuka Pharmaceutical, Teva Pharmaceutical and Sun Pharmaceutical.
Egypt Alzheimer’s Therapeutics Market Analysis
Egypt alzheimer’s therapeutics market valued at $13 Mn in 2022, projected to reach $30 Mn by 2030 with a 10.6% CAGR. The growing prevalence of Alzheimer's disease, which is fuelled by an aging population, is the main factor driving the market for drugs used to treat the condition. The leading pharmaceutical companies presently working in the industry are Eisai, Biogen, GlaxoSmithKline, Novartis, Pfizer, Roche, Johnson & Johnson, Eli Lilly, AstraZeneca and Merck & Co.
China Alzheimer’s Therapeutics Market Analysis
China alzheimer’s therapeutics market valued at $386 Mn in 2022, projected to reach $864 Mn by 2030 with a 10.6% CAGR. One key factor propelling the market for Alzheimer's treatment medications is the rising incidence of Alzheimer's disease which is driven by an aging population. The leading pharmaceutical companies currently operating in the market are Shanghai Green Valley Pharmaceutica, Eisai Co., Eli Lilly, Lundbeck, Johnson and Johnson, Novartis, Pfizer, Chongqing Zhifei Biological Products, Hengrui Medicine Co. and Jiangsu Hengrui Medicine.
Australia Lung Cancer Therapeutics Market Analysis
By 2030, it is anticipated that the Australia Lung Cancer Therapeutics Market will reach a value of $745 Mn from $358 Mn in 2022, growing at a CAGR of 9.6% during 2022-2030. The Lung Cancer Therapeutics Market in Australia is dominated by a few domestic pharmaceutical companies such as CSL Behring, Sirtex Medical, and Imugene. The Lung Cancer Therapeutics Market in Australia is segmented into different types of cancer and different therapy type. Some of the major factors affecting the Australian lung cancer therapeutics market are the prevalence of unhealthy lifestyles, demand for targeted therapies and the presence of highly efficient drugs.
Australia Breast Cancer Therapeutics Market Analysis
Increased incidence of breast cancer and the emergence of novel technologies for breast cancer treatments have propelled the Australian breast cancer therapeutics market from $218 Mn in 2022 to $641 Mn in 2030 with a CAGR of 14.4% for the year 2022-2030. The breast cancer therapeutics market is segmented by therapy, by cancer type, and by distribution channel. Novartis, GlaxoSmithKline Plc, and Kyowa Kirin Co. Ltd are leading players in the Australian breast cancer therapeutics market.
Australia Cardiovascular Drugs Market Analysis
Australia Cardiovascular Drug Market is at around $1.67 Bn in 2022 and is projected to reach $2.51 Bn in 2030, exhibiting a CAGR of 5.3% during the forecast period. The customized medicine, digital health integration, and changing environment of the Australian cardiovascular drug industry all point to great potential for long-term growth in the sector. The market is dominated by key players like Bristol-Myers Squibb Co, Pfizer, Bayer AG, Janssen Pharmaceuticals, Inc., AstraZeneca Inc., Sanofi-Aventis Inc., Novartis Pharmaceuticals, Merck & Co., Inc., Gilead Sciences, Inc., and F. Hoffman-La Roche Ltd.
Austria Infectious Disease Drugs Market Analysis
This report presents a strategic analysis of the Austria Infectious Disease Drugs Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges, and future outlook. This is one of the most comprehensive reports about the Austria Infectious Disease Drugs Market, offering unmatched value, accuracy, and expert insights.
Belgium Advanced Therapy Medicinal Products (ATMPs) Market Analysis
This report presents a strategic analysis of the Belgium Advanced Therapy Medicinal Products (ATMPs) Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges, and future outlook. This is one of the most comprehensive reports about the Belgium Advanced Therapy Medicinal Products (ATMPs) Market, offering unmatched value, accuracy, and expert insights.
Belgium Cardiovascular Diseases Therapeutics Market Analysis
Belgium's cardiovascular disease therapeutics market is projected to grow from $358 Mn in 2022 to $625 Mn in 2030 with a CAGR of 7.22% for the year 2022-30. The major market drivers include the increasing aging population and supportive reimbursement policies in Belgium. The Belgium cardiovascular disease therapeutics market is segmented by disease indication, drug type, route of administration, drug classification, mode of purchase, and by end user. Galapagos, Ablynx, and UCB are the major players in the Belgian cardiovascular disease therapeutics market.
